(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 21.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Ardelyx's revenue in 2025 is $333,615,000.On average, 6 Wall Street analysts forecast ARDX's revenue for 2025 to be $86,669,182,594, with the lowest ARDX revenue forecast at $83,592,718,837, and the highest ARDX revenue forecast at $91,767,145,470. On average, 6 Wall Street analysts forecast ARDX's revenue for 2026 to be $112,489,358,698, with the lowest ARDX revenue forecast at $93,440,644,505, and the highest ARDX revenue forecast at $122,205,235,019.
In 2027, ARDX is forecast to generate $141,697,530,142 in revenue, with the lowest revenue forecast at $111,102,840,555 and the highest revenue forecast at $170,210,178,130.